Eupraxia Pharmaceuticals (NASDAQ: EPRX) may still wear the “clinical-stage” name tag, but its stock has been behaving like it already found a seat at the grown‑ups’ table on Wall Street. Over the past year, shares have climbed roughly 160%, far outpacing the…